The impact of the COVID-19 pandemic on head and neck cancer patients.
作者信息
Chen Gaili, Wu Qiuji, Jiang Huangang, Zhong Yahua
机构信息
Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China.
Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China.
出版信息
Oral Oncol. 2020 Nov;110:104881. doi: 10.1016/j.oraloncology.2020.104881. Epub 2020 Jul 2.
Abstract
摘要
相似文献
1
The impact of the COVID-19 pandemic on head and neck cancer patients.2019年冠状病毒病大流行对头颈癌患者的影响。
Oral Oncol. 2020 Nov;110:104881. doi: 10.1016/j.oraloncology.2020.104881. Epub 2020 Jul 2.
2
The After Diagnosis Head and Neck cancer-specific Patient Concerns Inventory (HaNC-AD) as a pre-treatment preparation aid during the COVID-19 pandemic.在 COVID-19 大流行期间，作为治疗前准备辅助工具的诊断后头颈部癌症患者特定担忧量表 (HaNC-AD)。
Eur Arch Otorhinolaryngol. 2020 Jul;277(7):2141-2145. doi: 10.1007/s00405-020-05995-9. Epub 2020 Apr 27.
3
Surgical management of head and neck tumours during the SARS-CoV (COVID-19) pandemic.严重急性呼吸综合征冠状病毒（新冠病毒）大流行期间头颈部肿瘤的外科治疗
Acta Otorhinolaryngol Ital. 2020 Apr;40(2):87-89. doi: 10.14639/0392-100X-N0783. Epub 2020 Apr 10.
4
Disproportionate impact of COVID-19 pandemic on head and neck cancer survivors.新冠疫情对头颈癌幸存者的不成比例影响。
Head Neck. 2020 Jun;42(6):1329-1331. doi: 10.1002/hed.26170. Epub 2020 Apr 22.
5
COVID-19 pandemic & head and neck cancer patients management: The role of virtual multidisciplinary team meetings.新冠疫情与头颈癌患者管理：虚拟多学科团队会议的作用
Oral Oncol. 2020 Jun;105:104693. doi: 10.1016/j.oraloncology.2020.104693. Epub 2020 Apr 8.
6
Navigating the impact of COVID-19 on palliative care for head and neck cancer.应对 COVID-19 对头颈部癌症姑息治疗的影响。
Head Neck. 2020 Jun;42(6):1144-1146. doi: 10.1002/hed.26211. Epub 2020 Apr 27.
7
Should countries aim for elimination in the covid-19 pandemic?各国应致力于在新冠疫情中实现病毒消除吗？
BMJ. 2020 Sep 9;370:m3410. doi: 10.1136/bmj.m3410.
8
The novel coronavirus (COVID-19) infection in Hangzhou: An experience to share.杭州的新型冠状病毒（COVID-19）感染：一次分享经历
Infect Control Hosp Epidemiol. 2020 Jul;41(7):874-875. doi: 10.1017/ice.2020.62. Epub 2020 Mar 5.
9
Department of rehabilitation medicine in Shanghai response for coronavirus disease 2019: the impact and challenges.上海康复医学科对2019冠状病毒病的应对：影响与挑战
Eur J Phys Rehabil Med. 2020 Jun;56(3):345-346. doi: 10.23736/S1973-9087.20.06275-9. Epub 2020 Apr 15.
10
As normalcy returns, can China keep COVID-19 at bay?随着生活恢复正常，中国能控制住新冠疫情吗？
Science. 2020 Apr 3;368(6486):18-19. doi: 10.1126/science.368.6486.18.
引用本文的文献
1
Impact of the COVID-19 Infection on Head and Neck Cancer Treatment During Hospitalization.新冠病毒感染对住院期间头颈癌治疗的影响。
Cureus. 2024 May 19;16(5):e60578. doi: 10.7759/cureus.60578. eCollection 2024 May.
2
Impact of the COVID-19 Pandemic on Head and Neck Cancer Management: The Experience of the Maxillo-Facial Surgery Department of a French Regional Referral Center in a High-Incidence Area.2019年冠状病毒病大流行对头颈癌治疗的影响：法国一个高发病地区区域转诊中心颌面外科的经验
J Clin Med. 2024 Apr 22;13(8):2439. doi: 10.3390/jcm13082439.
3
Impact of COVID-19 pandemic on older cancer patients: Proposed solution by the International Geriatric Radiotherapy Group.新冠疫情对老年癌症患者的影响：国际老年放射治疗小组提出的解决方案
Front Oncol. 2023 Mar 7;13:1091329. doi: 10.3389/fonc.2023.1091329. eCollection 2023.
4
Brazilian Oral Medicine and public health system: The enormous impact of the COVID-19 Era.巴西口腔医学与公共卫生系统：新冠疫情时代的巨大影响。
Oral Dis. 2022 Apr;28 Suppl 1(Suppl 1):1001-1002. doi: 10.1111/odi.13677. Epub 2020 Nov 9.
本文引用的文献
1
The Management of Patients With Lung Cancer During the Outbreak of Coronavirus Disease 2019.2019年冠状病毒病疫情期间肺癌患者的管理
J Thorac Oncol. 2020 Jul;15(7):e106-e107. doi: 10.1016/j.jtho.2020.05.003. Epub 2020 May 23.
2
Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic.癌症、COVID-19 和预防原则：在全球大流行期间优先考虑治疗。
Nat Rev Clin Oncol. 2020 May;17(5):268-270. doi: 10.1038/s41571-020-0362-6.
3
SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China.SARS-CoV-2 在武汉一家三级医院癌症患者中的传播。
JAMA Oncol. 2020 Jul 1;6(7):1108-1110. doi: 10.1001/jamaoncol.2020.0980.
4
Fair Allocation of Scarce Medical Resources in the Time of Covid-19.新冠疫情期间稀缺医疗资源的公平分配
N Engl J Med. 2020 May 21;382(21):2049-2055. doi: 10.1056/NEJMsb2005114. Epub 2020 Mar 23.
5
Risk of COVID-19 for patients with cancer.癌症患者感染新冠病毒的风险。
Lancet Oncol. 2020 Apr;21(4):e181. doi: 10.1016/S1470-2045(20)30149-2. Epub 2020 Mar 3.
6
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.新型冠状病毒肺炎（SARS-CoV-2）感染的癌症患者：一项中国全国性分析。
Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14.
7
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.帕博利珠单抗单药或联合化疗对比西妥昔单抗联合化疗用于治疗复发性或转移性头颈部鳞状细胞癌（KEYNOTE-048）：一项随机、开放标签、III 期研究。
Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1.
8
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.帕博利珠单抗对比甲氨蝶呤、多西他赛或西妥昔单抗用于治疗复发性或转移性头颈部鳞状细胞癌（KEYNOTE-040）：一项随机、开放标签、III 期研究。
Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30.
9
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.帕博利珠单抗治疗铂类和西妥昔单抗难治性头颈癌：一项单臂II期研究的结果
J Clin Oncol. 2017 May 10;35(14):1542-1549. doi: 10.1200/JCO.2016.70.1524. Epub 2017 Mar 22.
10
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.纳武利尤单抗用于复发性头颈部鳞状细胞癌
N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8.
Zotero 插件